Cipla Share Price
Sector: Biotechnology & Drugs
1561.00 +35.50 (2.33%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
1528
Today’s High
1562.10
52 Week Low
1310.05
52 Week High
1702
1553.40 +27.50 (1.80%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
1525.90
Today’s High
1555.40
52 Week Low
1317.25
52 Week High
1702.05
Key Metrics
- Market Cap (In Cr) 126408.77
- Beta 0.33
- Div. Yield (%) 0.85
- P/B 4.61
- TTM P/E 24.74
- Peg Ratio 1.26
- Sector P/E 26.62
- Open Price 1529.45
- Prev Close 1525.5
Cipla Analysis
Price Analysis
-
1 Week0.71%
-
3 Months8.11%
-
6 Month2.49%
-
YTD-0.2%
-
1 Year8.51%
Risk Meter
- 28% Low risk
- 28% Moderate risk
- 28% Balanced Risk
- 28% High risk
- 28% Extreme risk
Recos
- Strong Sell
- Sell
- Hold
- Buy
- Strong Buy
Analysts' Views
- Ratings
- Current
- 1 W Ago
- 1 M Ago
- 3 M Ago
- Strong Buy
- 7
- 7
- 7
- 6
- Buy
- 12
- 12
- 12
- 12
- Hold
- 8
- 8
- 8
- 8
- Sell
- 4
- 4
- 4
- 6
- Strong Sell
- 1
- 1
- 1
- 1
- Total
- 32
- 32
- 32
- 33
Cipla News
Does one key drug approval make Cipla shares attractive amid tariff worries?
4 min read . 17 Apr 2025Cipla, Sun Pharma, Ipca Labs, JB Pharma drive pharma market growth in March’2025
1 min read . 14 Apr 2025Eli Lilly launches its blockbuster weight loss drug Mounjaro in India
3 min read . 21 Mar 2025Cipla Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2024
- Total Revenue
- 25774.09
- Selling/ General/ Admin Expenses Total
- 8433.06
- Depreciation/ Amortization
- 939.1
- Other Operating Expenses Total
- 649.33
- Total Operating Expense
- 20714.98
- Operating Income
- 5059.11
- Net Income Before Taxes
- 5701.9
- Net Income
- 4121.55
- Diluted Normalized EPS
- 53.76
- Period
- 2024
- Total Assets
- 32717.82
- Total Liabilities
- 6011.39
- Total Equity
- 26706.43
- Tangible Book Valueper Share Common Eq
- 272.41
- Period
- 2024
- Cashfrom Operating Activities
- 4133.91
- Cashfrom Investing Activities
- -2988.03
- Cashfrom Financing Activities
- -1200.43
- Net Changein Cash
- -48.99
- Period
- 2023
- Total Revenue
- 22753.12
- Selling/ General/ Admin Expenses Total
- 7507.04
- Depreciation/ Amortization
- 1017.83
- Other Operating Expenses Total
- 511.6
- Total Operating Expense
- 19047.03
- Operating Income
- 3706.09
- Net Income Before Taxes
- 4038.35
- Net Income
- 2801.91
- Diluted Normalized EPS
- 37.37
- Period
- 2023
- Total Assets
- 29463.28
- Total Liabilities
- 6055.5
- Total Equity
- 23407.78
- Tangible Book Valueper Share Common Eq
- 234.08
- Period
- 2023
- Cashfrom Operating Activities
- 3237.65
- Cashfrom Investing Activities
- -2388.51
- Cashfrom Financing Activities
- -958.29
- Net Changein Cash
- -96.78
- Period
- 2022
- Total Revenue
- 21763.34
- Selling/ General/ Admin Expenses Total
- 6908.86
- Depreciation/ Amortization
- 987.83
- Other Operating Expenses Total
- 463.91
- Total Operating Expense
- 18430.6
- Operating Income
- 3332.74
- Net Income Before Taxes
- 3493.27
- Net Income
- 2516.75
- Diluted Normalized EPS
- 33.28
- Period
- 2022
- Total Assets
- 27101.12
- Total Liabilities
- 6259.43
- Total Equity
- 20841.69
- Tangible Book Valueper Share Common Eq
- 198.32
- Period
- 2022
- Cashfrom Operating Activities
- 3325.9
- Cashfrom Investing Activities
- -1871.88
- Cashfrom Financing Activities
- -1599.79
- Net Changein Cash
- -132.32
- Period
- 2021
- Total Revenue
- 19159.59
- Selling/ General/ Admin Expenses Total
- 6031.69
- Depreciation/ Amortization
- 1000.57
- Other Operating Expenses Total
- 399.33
- Total Operating Expense
- 15960.05
- Operating Income
- 3199.54
- Net Income Before Taxes
- 3290.06
- Net Income
- 2404.87
- Diluted Normalized EPS
- 30.35
- Period
- 2021
- Total Assets
- 25151.89
- Total Liabilities
- 6825.36
- Total Equity
- 18326.53
- Tangible Book Valueper Share Common Eq
- 167.29
- Period
- 2021
- Cashfrom Operating Activities
- 3755.2
- Cashfrom Investing Activities
- -2387.18
- Cashfrom Financing Activities
- -1329.9
- Net Changein Cash
- 50.91
- Period
- 2020
- Total Revenue
- 17131.99
- Selling/ General/ Admin Expenses Total
- 6203.89
- Depreciation/ Amortization
- 1097.31
- Other Operating Expenses Total
- 421.32
- Total Operating Expense
- 15091.19
- Operating Income
- 2040.8
- Net Income Before Taxes
- 2178.18
- Net Income
- 1546.52
- Diluted Normalized EPS
- 19.8
- Period
- 2020
- Total Assets
- 23662.56
- Total Liabilities
- 7899.56
- Total Equity
- 15763
- Tangible Book Valueper Share Common Eq
- 135.56
- Period
- 2020
- Cashfrom Operating Activities
- 3068.45
- Cashfrom Investing Activities
- 104.04
- Cashfrom Financing Activities
- -2948.82
- Net Changein Cash
- 234.02
- Period
- 2019
- Total Revenue
- 16362.41
- Selling/ General/ Admin Expenses Total
- 5710.55
- Depreciation/ Amortization
- 1095.66
- Other Operating Expenses Total
- 495.46
- Total Operating Expense
- 14585.29
- Operating Income
- 1777.12
- Net Income Before Taxes
- 2079.14
- Net Income
- 1527.7
- Diluted Normalized EPS
- 20.97
- Period
- 2019
- Total Assets
- 23963.32
- Total Liabilities
- 8951.04
- Total Equity
- 15012.28
- Tangible Book Valueper Share Common Eq
- 127.03
- Period
- 2019
- Cashfrom Operating Activities
- 1691.14
- Cashfrom Investing Activities
- -1668.68
- Cashfrom Financing Activities
- -348.72
- Net Changein Cash
- -345.11
- Period
- 2024-12-31
- Total Revenue
- 7072.97
- Selling/ General/ Admin Expenses Total
- 1197.62
- Depreciation/ Amortization
- 279.8
- Other Operating Expenses Total
- 1622.35
- Total Operating Expense
- 5363.85
- Operating Income
- 1709.12
- Net Income Before Taxes
- 1916.09
- Net Income
- 1570.51
- Diluted Normalized EPS
- 19.43
- Period
- 2024-12-31
- Period
- 2024-12-31
- Period
- 2024-09-30
- Total Revenue
- 7051.02
- Selling/ General/ Admin Expenses Total
- 1207.88
- Depreciation/ Amortization
- 271.74
- Other Operating Expenses Total
- 1674.54
- Total Operating Expense
- 5437.17
- Operating Income
- 1613.85
- Net Income Before Taxes
- 1789.06
- Net Income
- 1302.53
- Diluted Normalized EPS
- 16.12
- Period
- 2024-09-30
- Total Assets
- 34655.28
- Total Liabilities
- 6293.18
- Total Equity
- 28362.1
- Tangible Book Valueper Share Common Eq
- 287.92
- Period
- 2024-09-30
- Cashfrom Operating Activities
- 2055.44
- Cashfrom Investing Activities
- -710.31
- Cashfrom Financing Activities
- -1182.8
- Net Changein Cash
- 177.57
- Period
- 2024-06-30
- Total Revenue
- 6693.94
- Selling/ General/ Admin Expenses Total
- 1194.23
- Depreciation/ Amortization
- 246.68
- Other Operating Expenses Total
- 1591.03
- Total Operating Expense
- 5224.82
- Operating Income
- 1469.12
- Net Income Before Taxes
- 1611.36
- Net Income
- 1177.64
- Diluted Normalized EPS
- 14.57
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 6163.24
- Selling/ General/ Admin Expenses Total
- 1084.23
- Depreciation/ Amortization
- 288.34
- Other Operating Expenses Total
- 1713.03
- Total Operating Expense
- 5135.72
- Operating Income
- 1027.52
- Net Income Before Taxes
- 1259.26
- Net Income
- 939.04
- Diluted Normalized EPS
- 11.63
- Period
- 2024-03-31
- Total Assets
- 32717.82
- Total Liabilities
- 6011.39
- Total Equity
- 26706.43
- Tangible Book Valueper Share Common Eq
- 272.41
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 4133.91
- Cashfrom Investing Activities
- -2988.03
- Cashfrom Financing Activities
- -1200.43
- Net Changein Cash
- -48.99
- Period
- 2023-12-31
- Total Revenue
- 6603.81
- Selling/ General/ Admin Expenses Total
- 1068.13
- Depreciation/ Amortization
- 233.43
- Other Operating Expenses Total
- 1568.62
- Total Operating Expense
- 5284.53
- Operating Income
- 1319.28
- Net Income Before Taxes
- 1473.81
- Net Income
- 1055.9
- Diluted Normalized EPS
- 14.82
- Period
- 2023-12-31
- Period
- 2023-12-31
- Period
- 2023-09-30
- Total Revenue
- 6678.15
- Selling/ General/ Admin Expenses Total
- 1091.1
- Depreciation/ Amortization
- 290.04
- Other Operating Expenses Total
- 1540.21
- Total Operating Expense
- 5234.44
- Operating Income
- 1443.71
- Net Income Before Taxes
- 1594.23
- Net Income
- 1130.91
- Diluted Normalized EPS
- 14
- Period
- 2023-09-30
- Total Assets
- 31377.09
- Total Liabilities
- 6551.69
- Total Equity
- 24825.4
- Tangible Book Valueper Share Common Eq
- 252.21
- Period
- 2023-09-30
- Cashfrom Operating Activities
- 1688.51
- Cashfrom Investing Activities
- -741.85
- Cashfrom Financing Activities
- -708.18
- Net Changein Cash
- 237.77
- Period
- 2023-06-30
- Total Revenue
- 6328.89
- Selling/ General/ Admin Expenses Total
- 1066.58
- Depreciation/ Amortization
- 239.21
- Other Operating Expenses Total
- 1531.57
- Total Operating Expense
- 5074.19
- Operating Income
- 1254.7
- Net Income Before Taxes
- 1374.6
- Net Income
- 995.7
- Diluted Normalized EPS
- 12.33
- Period
- 2023-06-30
- Period
- 2023-06-30
- Period
- 2023-03-31
- Total Revenue
- 5739.3
- Selling/ General/ Admin Expenses Total
- 964.84
- Depreciation/ Amortization
- 346.22
- Other Operating Expenses Total
- 1537.35
- Total Operating Expense
- 5094.2
- Operating Income
- 645.1
- Net Income Before Taxes
- 745.37
- Net Income
- 525.65
- Diluted Normalized EPS
- 8.1
- Period
- 2023-03-31
- Total Assets
- 29463.28
- Total Liabilities
- 6055.5
- Total Equity
- 23407.78
- Tangible Book Valueper Share Common Eq
- 234.08
- Period
- 2023-03-31
- Cashfrom Operating Activities
- 3237.65
- Cashfrom Investing Activities
- -2388.51
- Cashfrom Financing Activities
- -958.29
- Net Changein Cash
- -96.78
- Period
- 2022-12-31
- Total Revenue
- 5810.09
- Selling/ General/ Admin Expenses Total
- 948.69
- Depreciation/ Amortization
- 272.11
- Other Operating Expenses Total
- 1449.55
- Total Operating Expense
- 4674.65
- Operating Income
- 1135.44
- Net Income Before Taxes
- 1218.06
- Net Income
- 800.96
- Diluted Normalized EPS
- 9.92
- Period
- 2022-12-31
- Period
- 2022-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Cipla Technical
Moving Average
SMA
- 5 Day1529.99
- 10 Day1502.28
- 20 Day1479.53
- 50 Day1464.15
- 100 Day1469.41
- 300 Day1517.56
Cipla Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Sun Pharmaceutical Industries
- 1834.95
- 48.1
- 2.69
- 1960.2
- 1376.75
- 440255.23
- Divis Laboratories
- 6077.8
- 68.6
- 1.14
- 6448.75
- 3674.2
- 161346.49
- Cipla
- 1561
- 35.5
- 2.33
- 1702
- 1310.05
- 126408.77
- Torrent Pharmaceuticals
- 3339.35
- 103.4
- 3.2
- 3589.95
- 2513.05
- 112872.43
- Dr Reddys Laboratories
- 1196.35
- 22.8
- 1.94
- 1420.2
- 1025.9
- 100034.24
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Sun Pharmaceutical Industries
- 42.83
- 6.74
- 11.27
- 14.23
- Divis Laboratories
- 99.57
- 11.76
- 18.97
- 26.38
- Cipla
- 28.38
- 4.61
- 13.5
- 12.66
- Torrent Pharmaceuticals
- 68.37
- 15.99
- 20.64
- 13.18
- Dr Reddys Laboratories
- 17.78
- 3.46
- 16.73
- 14.63
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 13-May-25
- Audited Results & Final Dividend
- 28-Jan-25
- Quarterly Results
- 29-Oct-24
- Quarterly Results
- 26-Jul-24
- Quarterly Results
- 10-May-24
- Audited Results & Final Dividend
- 25-Jan-24
- Quarterly Results
- 22-Jan-24
- Quarterly Results
- 27-Oct-23
- Quarterly Results
- 26-Jul-23
- Quarterly Results
- 12-May-23
- Audited Results & Final Dividend
- Meeting Date
- Announced on
- Purpose
- 15-Oct-24
- 17-Sept-24
- POM
- 20-Aug-24
- 10-May-24
- AGM
- 10-Aug-23
- 12-May-23
- AGM
- 26-Aug-22
- 29-Jul-22
- AGM
- 25-Aug-21
- 27-Jul-21
- AGM
- 27-Mar-21
- 23-Feb-21
- POM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 10-May-24
- 02-Aug-24
- 02-Aug-24
- 13
- 12-May-23
- 21-Jul-23
- 21-Jul-23
- 8.5
- 27-Jul-22
- 10-Aug-22
- 08-Aug-22
- 5
- 14-May-21
- -
- 09-Aug-21
- 5


